Nvidia among investors in xAI’s $20bn capital raise - Bloomberg News
Investing.com - BeiGene (NASDAQ:BGNE) stock fell Thursday amid reports that President Trump is considering an executive order targeting Chinese biotech companies and data, creating ripples across the biotech sector.
RBC Capital notes the news has created volatility in the sector, driving weakness for high-quality companies that may be incorrectly perceived as having high China risk, while potentially contributing to broader U.S. biotech industry strength.
The bank believes some version of an executive order on this topic is likely, with changes to M&A and the use of ex-U.S. clinical trial data potentially having the most significant impacts, though limited details make it challenging to fully gauge the impact.
RBC identifies Oncorus (NASDAQ:ONC) and Legend Biotech (NASDAQ:LEGN) as high-quality companies caught in the downside that are unlikely to be materially impacted. For Legend Biotech, which maintains a healthy current ratio of 4.71 and impressive revenue growth of 74.75%, the sell-off presents an attractive entry point. According to InvestingPro analysis, the stock appears undervalued, with RSI indicating oversold conditions.
Companies that may benefit from increased U.S. M&A include Insmed (NASDAQ:INSM), Edgewise Therapeutics (NASDAQ:EWTX), Cytokinetics (NASDAQ:CYTK), Crinetics (NASDAQ:CATX), and Xenon Pharmaceuticals (NASDAQ:XENE), according to the bank’s analysis.
In other recent news, Legend Biotech Corporation reported its second-quarter earnings for 2025, showcasing substantial revenue growth. The company achieved revenue of $255.06 million, surpassing analyst forecasts of $234.23 million. Despite this revenue success, Legend Biotech posted a larger-than-expected loss per share of $0.34, which was below the anticipated loss of $0.1153. Additionally, the company announced the appointment of Carlos Santos as its new Chief Financial Officer, effective immediately. Santos will focus on maintaining a strong financial position and steering the company toward profitability by 2026. In related developments, RBC Capital raised its price target for Legend Biotech to $77, maintaining an Outperform rating. This adjustment came after the company reported strong demand and successful manufacturing for its Carvykti product. These developments highlight Legend Biotech’s ongoing efforts to strengthen its financial and operational standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.